Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: A retrospective study

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 561-566

  Hursting, Marcie J ^a   Verme Gibboney, Catherine N ^b  

^a Clinical Science Consulting   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Argatroban; Bleeding; Heparin induced thrombocytopenia; Risk factor

Indexed keywords

ARGATROBAN; WARFARIN; ANTICOAGULANT AGENT; HEPARIN; PIPECOLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; TREATMENT DURATION; ADOLESCENT; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; LUNG DISEASE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; DRUG MONITORING; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; ODDS RATIO; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTOPENIA; THROMBOSIS; YOUNG ADULT;

EID: 59449084599     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181926928     Document Type: Article

References (43)

1. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:340S-380S.
2. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol. 2006;133:259-69.
3. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361-369.
4. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
5. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163: 1849-1856.
6. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006;129:1407-1416.
7. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329.
8. Levine R, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest. 2006;129: 1167-1175.
9. De Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother. 2003;37:1237-1240.
10. Reichert MG, MacGregor DA, Kincaid EH, et al. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother. 2003;37:652-654.
11. Williamson DR, Boulanger I, Tardif M, et al. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy. 2004;24:409-414.
12. Koster A, Buz S, Hetzer R, et al. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg. 2006;132:699-700.
13. Beiderlinden M, Treschan TA, Gorlinger K, et al. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007;41:749-754.
14. Begelman SM, Baghdasarian SB, Singh IM, et al. Argatroban anti-coagulation in intensive care patients: effects of heart failure and multiple organ system failure. J Intensive Care Med. 2008;23:313-320.
15. Hoffman WD, Czyz Y, McCollum D, et al. Reduced argatroban dosing after coronary artery bypass graft surgery. Ann Pharmacother. 2008;42: 309-316.
16. Smythe MA, Stephens JL, Koerber JM, et al. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005;11:371-374.
17. Kiser TH, Jung R, MacLaren R, et al. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy. 2005;25:1736-1745.
18. Jang IK, Baron SJ, Hursting MJ, et al. Heparin-induced thrombocytopenia and argatroban therapy in women. J Womens Health (Larchmt). 2007;16: 895-901.
19. Kodityal S, Nguyen PH, Kodityal A, et al. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med. 2006;21:86-92.
20. Cormack GM, Kaufman LJ. Severe heparin-induced thrombocytopenia: when the obvious is not obvious, a case report. J Med Case Reports. 2007; 1:13.
21. Dager WE, White RH. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Ann Pharmacother. 2003;37: 1232-1236.
22. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006;108: 1492-1496.
23. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: effects on aPTT, and clinical relevance. Blood. 2000;96:2373-2378.
24. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
25. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment. The Seventh ACCP Conference on Antithrom-botic and Thrombolytic Therapy. Chest. 2004;126:287S-310S.
26. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673-685.
27. Voeltz MD, Patel AD, Feit F, et al. Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention. Am J Cardiol. 2007;99:1513-1517.
28. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22:255-271.
29. Fradette C, du Souich P. Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab. 2004;5:257-271.
30. Power BM, Forbes AM, van Heerdon P, et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34:25-56.
31. Swan SK, St. Peter J, Lambrecht L, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy. 2000;20:756-770.
32. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580.
33. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347-360.
34. Wouters EFM. Chronic obstructive pulmonary disease - 5: systemic effects of COPD. Thorax. 2002;57:1067-1070.
35. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2003;37:970-975.
36. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother. 2004;38:25-29.
37. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth. 2002;49:S11-S25.
38. Murray PM, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004;66:2446-2453.
39. Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39:231-236.
40. Malherbe S, Tsui BC, Stobart K, et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology. 2004;100:443-445.
41. Alsoufi B, Boshkov LK, Kirby A, et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004;7:155-171.
42. Yee AJ, Kuter DJ. Successful recovery after an overdose of argatroban. Ann Pharmacother. 2006;40:336-339.
43. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.